Abstract. Previously, the human high mobility group protein member HMGA2 mRNA was reported to be expressed in peripheral blood of patients with breast cancer, but not in healthy individuals. Expression of HMGA2 in blood was suggested to be an independent indicator of poor prognosis in metastatic breast cancer. These very promising findings propose HMGA2 as a potential marker for the detection of circulating tumor cells in peripheral blood. Therefore, we analyzed peripheral blood specimens from healthy controls and patients with breast tumors for HMGA2 expression using TaqMan ® real-time RT-PCR to test if HMGA2 is a suitable marker for the early detection of breast cancer and monitoring therapy response in peripheral blood. Furthermore, we examined the possible involvement of HMGA2 expression in invasion investigated by an in vitro invasion assay using established breast cell lines. HMGA2 expression was detected in peripheral blood of breast cancer patients as well as of healthy individuals. No significant association of HMGA2 expression with any clinical or histopathological data was apparent. However, there was a significant correlation of HMGA2 expression in invasive and non invasive breast cell lines (p=0.0056). Although, HMGA2 obviously contributes to invasion it is not a specific marker for the detection of circulating tumor cells in peripheral blood.
Introduction
Metastasis is a sequential series of steps including cellular separation from the primary tumor, invasion through surrounding tissues and basement membranes, entry and survival in the circulation (blood and lymphatics), extravasation into the surrounding tissue, and formation of secondary tumors. In this complex process, among several proteins, the high mobility group protein member 2 (HMGA2) is thought to play an important role. Its involvement in oncogenesis is based on observations on its high expression in invasive ductal breast tumors with high histological grade and in a number of human malignant tumors but not in the normal tissues (1, 2) . Evidence of its role in the development of a variety of benign tumors, mostly of mesenchymal origin, including lipomas, uterine leiomyomas, fibroadenomas of the breast, aggressive angiomyxomas, endometrial polyps and pulmonary hamartomas has been provided by cytogenetic studies (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) . Although the HMGA2 gene is probably one of the most commonly rearranged genes in human neoplasms its precise function in the development and progression of tumors is still unknown (6, 10, 13, 14) . Originally, HMGA2 was discovered as an acid-soluble nuclear protein that was expressed at high levels following transformation of fibroblasts and thyroid cells in oncogenic viruses and during embryonic development (2) . Recently, HMGA2 mRNA expression was reported in the peripheral blood of metastatic breast cancer patients and of leukemia patients, but not in the blood of healthy individuals (1, (15) (16) (17) (18) .
Based on these very remarkable findings HMGA2 can be regarded as a suitable marker for the detection of circulating tumor cells in peripheral blood. As circulating tumor cells are shedded into the circulation by tumors probably even at the very beginning of disease and are made responsible for the development of metastases in some patients without apparent distant metastases at the time of initial diagnosis, their detection might be useful for early diagnosis, selection of therapy as well as monitoring therapy response.
In view of the published data and in order to evaluate the suggested diagnostic and prognostic relevance of HMGA2 mRNA expression in breast cancer patients, we investigated HMGA2 expression levels in peripheral blood specimens of breast cancer patients and healthy individuals. Other than former studies we used highly sensitive and specific TaqMan real-time RT PCR assays for the detection of rare HMGA2 transcripts. Further, to determine the involvement of HMGA2 in invasion, which is one of the critical steps in oncogenesis, we analyzed a possible correlation of the HMGA2 expression with the in vitro invasiveness of breast cell lines. (19, 20) .
Materials and methods

Blood
Erythrocyte lysis and RNA isolation. EDTA-blood (20 ml) was diluted in erythrocyte lysis solution [155 mM NH 4 Cl; 10 mM NaHCO 3 ; 100 mM Na 2 EDTA (pH 8.0)] and centrifuged at 300 x g for 10 min at 4˚C. The cell pellets were washed once in PBS and dissolved in guanidine thiocyanate solution. Total RNA from white blood cells and cell lines was extracted from the lysates by isopycnic centrifugation as described previously, followed by DNaseI digestion and further purification using the RNeasy Kit from Qiagen (Qiagen, Hilden, Germany) (21) . The concentration and purity of total RNA was determined by ultraviolet spectrophotometry at 260 and 280 nm. RNA integrity was checked with an Agilent 2100 Bioanalyzer using the RNA 6000 LabChip kit (Agilent Technologies, Waldbronn, Germany).
Reverse transcription. Reverse transcription (RT) reactions were carried out in a 20 µl volume containing 500 ng RNA, Table I . Characteristics of 47 breast cancer patients. 300 ng random hexamer primers (Amersham Biosciences, Upsala, Sweden), 0.5 mM each dNTP and 4 U OmniScript Reverse Transcriptase (Qiagen, Hilden, Germany), and 20 U RNAsin (ViennaLab, Vienna, Austria). RT reaction mixtures were incubated for 1 h at 37˚C, followed by 5 min at 95˚C. The resulting cDNAs were diluted one-to-four and used as a template in the subsequent PCR.
TaqMan real-time RT-PCR. TaqMan real-time RT-PCR was performed using the 2X TaqMan Universal PCR Master Mix with the ABI Prism 5700 sequence detection system (Applied Biosystems, Foster City, CA, USA). Reactions were conducted in a total volume of 25 µl containing 4 µl of diluted cDNA template, 12.5 µl of 2X TaqMan Universal PCR Master Mix, and 1.25 µl of 20X HMGA2 solution containing specific primers and probe (assay-on-demand, assay_ID: Hs00171569 _m1; Applied Biosystems, Foster City, CA, USA).
The Gene Amp 5700 sequence detection system software was used for PCR cycling reaction, real-time data collection and analysis. PCR mixtures were pre-incubated at 50˚C for 2 min, then 95˚C for 10 min, followed by 40 cycles of two step incubations at 95˚C for 15 sec and 60˚C for 1 min. All amplification reactions were carried out in duplicate. Then the data were normalized to the expression of ß2-microglobulin using the TaqMan PDAR B2M RNA Control Reagent (Applied Biosystems). Final quantitation was done using the comparative C T method and is reported as relative amount or the n-fold difference relative to the cell line BT-549 cDNA which was included as a calibrator in each real-time PCR experiment. To verify that the amplification efficiencies of B2M and HMGA2 were comparable, seven dilutions of cDNA preparations in duplicate were amplified to obtain dilution curves (Fig. 1) . There are no significant differences in HMGA2 transcript levels between controls, benign and malignant breast lesions (upper). Even no differences were observed among several different histological types of breast cancer (ILC, invasive lobular carcinoma; IDC, invasive ductal carcinoma; DCIS, ductal carcinoma in situ), benign tumors and healthy volunteers (lower). Table II . Relative quantitation of HMGA2 expression using the comparative C T method and in vitro invasiveness.
-------------------------------------------------
HMGA2 HMGA2 Invasiveness expression expression relative to BT- 549  ------------------------------------------------ 
n.e., no HMGA2 expression was detected.
Statistical analysis. To compare HMGA2 expression between blood samples of healthy controls, breast tumor patients, and breast cell lines the Mann-Whitney U test was used. A p-value of <0.05 was considered statistically significant. Possible associations between the HMGA2 expression and tumor type, differentiation grade, tumor size and nodal status were calculated by the Mann-Whitney U test.
Results
The highly sensitive TaqMan real-time RT-PCR analysis was performed to compare the HMGA2 mRNA expression in blood specimens of healthy individuals and patients with either benign or malignant breast lesions. All blood samples analyzed showed detectable HMGA2 expression. Similar levels of HMGA2 expression were measured both for the cancer patients and healthy individuals (Fig. 2) . In control blood samples the maximum level of HMGA2 expression was about 170-fold higher than the lowest level of expression.
Further, we screened 27 breast cell lines for expression of HMGA2. Except BT-483, CAMA-1, MDA-MB-134-VI, MDA-MB-453, SK-BR-3, UACC-812, and UACC-893 HMGA2 expression was noted in all tested cell lines (Table II, Fig. 3) .
The correlation between HMGA2 expression in invasive and non invasive breast cell lines was found to be highly significant (p=0.0056). There were no significant associations of HMGA2 expression with any clinical or histopathological data in blood of patients with either benign or malign breast lesions.
Discussion
Markers which are expressed in circulating tumor cells but not in blood cells will be suitable for both the early detection of cancer and monitoring therapy response in peripheral blood specimens. Studies reporting HMGA2 expression in blood of metastatic breast cancer patients or leukemia patients but not in healthy individuals let HMGA2 appear as a possible marker for the detection of circulating tumor cells (15, 16, 18) . Therefore, we determined HMGA2 expression levels in blood specimens of patients with benign or malignant breast lesions and healthy cancer-free individuals. Other than former studies we used quantitative TaqMan ® real-time RT-PCR. To the best of our knowledge, this is the first report showing HMGA2 expression in healthy blood specimens. This discrepancy to previous reports can be explained by the use of a different detection technique. As TaqMan real-time RT-PCR is advantageous over conventional RT-PCR with respect to sensitivity and specifity, rare transcripts are detected easier. That is very likely the reason for the apparent background expression arising from white blood cells, which makes HMGA2 unsuitable for the detection of circulating tumor cells. As a consequence, we found no significant differences in HMGA2 expression levels in blood specimens of patients with breast lesions and healthy controls. Although no differences between HMGA2 expression in blood specimens of patients with relapse and healthy individuals were apparent, this was already reported in blood specimens from patients with metastatic breast cancer (16, 17) . On the one hand this discrepancy might occur due the small sample size used in the current study, and on the other hand it is caused by the highly sensitive detection method. Since white blood cells apparently contribute to the measurable HMGA2 expression level, one might decrease this undesirable signal by enrichment of tumor cells or even their isolation. In that case, HMGA2 might still be considered a marker for recurrence of breast cancer and metastasis. The fact that in our study there was no correlation between any of the clinical or histo- pathological factors and HMGA2 expression is consistent with previous data (17) .
Apart from analyzing HMGA2 expression in blood specimens we determined the HMGA2 expression levels in breast cell lines to investigate its involvement in invasion. Significant differences could be found between invasive and non invasive breast cell lines, indicating that HMGA2 contributes to tumor invasion. This finding is consistent with reported ectopically HMGA2 expression in human invasive breast cancer tissues (1).
In conclusion, as HMGA2 is expressed in normal peripheral blood cells, it is not a specific marker for the detection of circulating tumor cells in blood. It does not have a prognostic relevance in blood of patients with breast tumors. Furthermore, there is an association of HMGA2 expression and the invasiveness of breast cell lines indicating that HMGA2 is involved in steps required for invasion.
